113 results about "Tumour site" patented technology

The invention relates to a preparation method of meso-porous silicon nanoparticle with reducing/enzyme dual response and targeting property. The preparation method of the meso-porous silicon nanoparticle with the reducing/enzyme dual response and targeting property comprises the following steps: synthesizing a meso-porous silicon nanoparticle; modifying a disulfide bond on the surface of the meso-porous silicon nanoparticle by adopting a chemical method, and grafting the disulfide bond with hyaluronic acid as a targeting molecule; by taking carboxyl on the targeting molecule as a reaction site, modifying polyethylene glycol to the surface of the compound nanoparticle, thus improving biocompatibity of the nanoparticle, and connecting the hyaluronic acid molecule with the targeting effect to the surface of the nano particle, thus obtaining the meso-porous silicon nanoparticle diagnosis agent with medicinal response releasing and imaging functions. The prepared particle has good dispersity, is uniform in particle size and is easy to prepare, the prepared multifunctional diagnosis agent has good biocompatibility, medicine can be released in a tumour part in a responding manner, and diagnosis integration of the tumour can be realized.

The invention relates to an NRP-1 ligand polypeptide-polyethylene glycol-phosphatide compound, an active targeting liposome drug delivery system mediated thereby and a preparation method thereof. A carrier system comprises; a. phosphatide; b. cholesterol; c. methoxy polyethylene glycol-phosphatide compound; and d. polypeptide-polyethylene glycol-phosphatide compound containing an RPARPAR sequence. The above components are in a molar ratio of: a:b=5:1-1:5, a:c=1000:0.1-1000:100, and a:d=1000:0.1-1000:100. The system can carry out intravenous route drug administration and target the drug to a tumour position according to tumour EPR effect and RPARPAR mediation effect. The liposome drug delivery system can be applied to tumour diagnosis or targeting delivery of a treatment medicament.

The invention relates to an aptamer-based targeted delivery microRNA nanometer carrier as well as a preparation method and application thereof. A targeting molecule is a sulfydryl-modified MUC-1molecule, and can be combined with cancer-inhibiting microRNA-34a, so that a MicroRNA-nanodiamond-protamine complex (MNPs) becomes AMNPs with an active targeting function; through electrostatic interaction, a negatively-charged aptamer-microRNA (Apt-miR) chimera is adsorbed to a cationic protamine-nanodiamond carrier to form a trinary compound carrier. The therapeutic effect of a nanotransport system on a non-small cell lung cancer is researched; the Apt-miR chimera is low in immunogenicity; the modified MUC-1 aptamer has high chemical stability in vivo, and can be chemically synthesized easily; in order to improve the transfection efficiency, a protamine-modified nanodiamond material (NPs) is used for helping miRNA to increase accumulation in a tumor part through permeability and retention enhancing effects.

The invention discloses a medicament for treating neovascularization diseases. The medicament employs miRNA-132 and miRNA-155 as targets and two specific antagomirs, antagomir-132 and antagomir-155, as the basic components. The above two micronucleus acids are knocked down in a lesion at the same time, so as to inhibit excessive proliferation of new vessels to achieve therapeutic effect. To ensure the effective application of the drug, the invention adopts in vivo delivery vectors, such as a histidine-lysine polypeptide polymer HKP and a ligand targeted delivery nanoparticle system RGD-PEG-HKP, in order to improve the specificity and efficiency of medicament delivered into angiogenesis sites (eye or tumor).

A system and method for therapy and diagnosis of a human or animal. At least one coupling element for coupling of radiation couples radiation from at least a first radiation source to a tumour site and/or from said second radiation source to said site and/or from said site to a detector. The coupling elements are combinations of at least one translatory distributor, at least one rotary distributor, and at least one operation mode selector means for directing either said therapeutic radiation or said diagnostic radiation to said site through said at least one first radiation conductor. The system may be used for interactive interstitial photodynamic tumour therapy. The system and method according to the invention combines the advantages of purely mechanical and purely non-mechanical solutions in a new and synergetic way.

The invention relates to a charge reversal Pulullan derivative and a synthesis method and application thereof. The Pulullan derivative is composed of a Pulullan framework, a multi-amino modified group and a beta-carboxylic acid amide modified group, has remarkable liver/liver cancer targeting property, and can quickly respond to a faintly acid tumor microenvironment and a cell endosome/lysosome so as to achieve reversal from electronegativity to electropositivity. By modifying poly(beta-amino ester) (PBAE)/polylactic acid-polyglycolic acid copolymer (PLGA) composite nanoparticles with the Pulullan derivative, liver cancer targeted delivery of nanoparticles can be mediated efficiently, effective release of a carried drug at the tumor position is achieved, and the charge reversal Pulullan derivative is a liver/liver cancer targeted carrier material with excellent performance for drugs, genes and image contract agents and has broad application space.

The present invention relates to chemokine-mucin fusions linked to glycosylphosphatidylinositol (GPI)-anchors and their use as anti-cancer adjuvants and as agents in tissue regeneration and suppression of vascular damage. GPI-linked chemokines are incorporated in the surface membrane of tumour cells and effect a recruitment of cytotoxic immune cells to the tumour site following injection in vivo. Leukocytes, cytotoxic T-cells and NK cells target the chemokine-GPI-anchored tumour cells and modulate cell-mediated lysis of the tumour cells. The efficiency of GPI-anchoring and modulation of immune cells can be further enhanced by linking the chemokine to a mucin domain followed by the GPI-anchor. The GPI-anchored chemokines, with or without mucin domain, are remarkably useful for the inhibition of tumour growth, tissue regeneration, and suppression of acute vascular damage to allografts.

The invention provides a preparation method and application of a PH reversible controlled release meso-porous silicon nanometer drug delivery system. The PH reversible controlled release meso-porous silicon nanometer drug delivery system comprises meso-porous silicon nanoparticles and a compact polytannic acid layer, wherein the meso-porous silicon nanoparticles are loaded with drugs; and the compact polytannic acid layer is tightly wrapped on the surface of the meso-porous silicon nanoparticles so as to adjust and control specific release of the drugs at a tumour site. According to the preparation method and application of the PH reversible controlled release meso-porous silicon nanometer drug delivery system in the invention, the drugs are loaded by taking the meso-porous silicon nanoparticles as the carrier; tannic acid and a polyamine molecular cross-linking agent with amino at both ends perform spontaneous oxidation polymerization in an alkaline condition to form the polytannic acid layer, which is used as intelligent gating molecules wrapped on the surface of drug loaded meso-porous silicon; therefore, PH reversible responsive controlled release is realized; finally, by meansof Schiff base reaction or Michael addition reaction, a targeting agent with amino or sulfydryl is covalently crosslinked on the surface of the polytannic acid layer, so that specific targeted drug delivery on cancer cells is realized; the designed synthetic nanometer drug delivery system can effectively solve the problem that the traditional stimulus responsive drug delivery system is nearly irreversible; and thus, the secondary toxicity possibly due to the fact that a drug carrier has drug residues can be avoided.

A system and method for interactive therapy and diagnosis of a human or animal comprising at least one first radiation source for emission of a diagnostic radiation, at least one second radiation source for emission of a therapeutic radiation, and at least one radiation conductor adapted to conduct radiation to a tumour site at or in said human or animal. A non-mechanical operation mode selector directs the therapeutic radiation and/or the diagnostic radiation to the tumour site through the radiation conductors. The operation mode selector means is preferably a non-mechanical optical switch and/or an optical combiner. The system may be used for interactive interstitial photodynamic tumour therapy.

The invention discloses a radioactive particle automatic implanting device. The radioactive particle automatic implanting device includes a radioactive particle storage device, a radioactive particle implanting needle, a push rod, a driving cylinder and a main controller, wherein the radioactive particle storage device is internally provided with a radioactive particle storage cavity, and a radioactive particle delivery channel is formed in the bottom of the radioactive particle storage cavity; a radioactive particle implanting channel is horizontally formed in the lower end of the radioactive particle storage device, and a first end of the radioactive particle implanting channel is an implanting needle insertion end; a second end is a push rod insertion end, and a radioactive particle lead-in mouth is formed in the part, close to the implanting needle insertion end, of the inner top surface of the radioactive particle implanting channel; a radioactive particle slide path is arranged between the radioactive particle lead-in mouth and the bottom of the radioactive particle delivery channel, and the radioactive particle implanting needle is connected with the implanting needle insertion end; the front end of the push rod is inserted into the push rod insertion end, and the rear end is connected with the driving cylinder. The radioactive particle automatic implanting device has the advantages of automatically implanting large-batch radioactive particles into a tumor part of the body of a patient, and the use effect is good.

The invention discloses a cabazitaxel phospholipid composition, a preparation method thereof and an application. The cabazitaxel phospholipid composition comprises a cabazitaxel lipid complex, phospholipid and cholesterol and solves the problems that drugs are unstable, preparation steps before clinical use are complicated, an existing lipid preparation has poor in vitro and vivo stability and the like, in vivo circulation time of the drugs is prolonged, the composition has a certain targeting function, the drugs are enriched on a tumor site, toxic and side effects are reduced, and bioavailability is greatly improved.

The invention provides a nano-particle for mediating cascade reaction, and a preparation method thereof. The nano-particle provided by the invention comprises a core particle and a wrapping layer wrapping the core particle; the core comprises a metal-organic framework MIL-100 and dihydroporphin e6 loaded on the metal-organic framework MIL-100; and the wrapping layer is a hyaluronic acid layer. Bymeans of the nano-particle in the invention, cascade reaction at a tumour site can be realized; synergistic combination therapy of chemical kinetics and optical dynamics is realized; and thus, the better therapeutic effect of tumour is achieved.

The invention relates to the technical field of medical appliances and discloses an electric-pulse ablation device capable of cooperating with drug administration. The electric-pulse ablation device comprises an endoscopic tube and a drug administration ablation assembly, wherein the drug administration ablation assembly comprises an intervention catheter, and a tube fixing member is arranged at the front end of the endoscopic tube. The electric-pulse ablation device can be intervened into a body of a patient in a non-invasive or minimally-invasive manner, the intervention catheter can go deep into the body through a natural orifice of the human body directly by dint of the existing endoscopic working passage, and then, a tumor region is ablated by using electric pulses; medicated liquid injection operation can also be carried out through the intervention catheter, and the treatment effect on a tumor can be effectively improved due to combined use of an ablation technology and medicated liquid; and relative movement between a dilation body and electrodes can be driven through an electric push-and-pull mechanism, two groups of electrode tips pricked into tumor tissue can be far away from each other due to wedge-shaped lugs arranged on the electrodes, then, the ablation diameter is increased greatly, the applicability of electric-pulse ablation is improved, and the difficulty of ablation operation is simplified.

The invention relates to a preparation method of porphyrin-terminated nano-scale fluorescent polyrotaxane. The preparation method comprises the following steps: mixing pseudorotaxane, porphyrin, PyBOP, DMAP and a solvent (anhydrous DMF), putting the mixture into a shaking table, reacting at 2-8 DEG C for 12-24 hours, adding methanol after the reaction is finished to separate out a solid, washing the solid, dispersing the solid into DMSO, adding deionized water, separating out a light pink precipitate, washing, and freeze-drying to obtain the product. The invention also provides an antitumor drug prepared by using the nano-scale fluorescent polyrotaxane as a drug carrier. Experiments show that the nano-scale fluorescent polyrotaxane can trace drugs, improve the enrichment of the drugs at tumor sites and reduce the toxic and side effects of the drugs on organisms, thereby improving the treatment effect of the drugs on tumors.

The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and/or TAAs that are shared with the antigens present in patients' tumour. In each case, tumour cells are utilised as the starting point on the premise that only rumour cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.

The invention relates to a chemical structure and a preparation method of a tumor imaging agent, and in particular relates to a single photon emission computed tomography (SPECT) technetium (99mTc)-labeled RGD polypeptide trimer medicine, namely 99mTc-4P-RGD3. The tumor imaging medicine is combined with an integrin alphavbeta3 in a ligand mode so as to achieve an application of imaging a tumor part. The preparation method comprises the following implementing steps: linking HYNIC-Osu to 4P-RGD3 so as to obtain a ligand HYNIC-4P-RGD3, and chelating the HYNIC in the ligand with 99mTc so as to obtain the 99mTc-4P-RGD3 tumor imaging agent. A research on animal in-vivo distribution and a tumor imaging step proves that the tumor imaging agent is relatively high in tumor uptake and lower in background uptake to normal organs in a whole body, and the definition of tumor image of the whole body is improved; a drug metabolism experimental step shows that the 99mTc-4P-RGD3, after metabolized in an animal body, can be still discharged out of the body in a prototype mode. The technetium-labeled integrin alphavbeta3 tumor imaging agent (99mTc-4P-RGD3) prepared by the technical means disclosed by the invention can be used for solving a problem of high background uptake of other technetium-labeled RGD medicines in animal body, so that the technetium-labeled RGD medicine is more suitable for the assessment of tumors in whole body.

The invention discloses a camptothecin and Arg-Gly-Asp (RGD) polypeptide conjugate as well as a preparation method and application thereof. The structure of the polypeptide coupled camptothecin drug includes the following three parts: A, an RGD targeting peptide; B, a linker; and C, anticancer drug camptothecin, wherein the RGD polypeptide and the camptothecin are connected by using succinic anhydride as a connecting arm; and the synthesized RGD-camptothecin polypeptide drug conjugate can deliver the camptothecin to tumor cells, tissue, tumor microenvironment and other tumor sites to achieve the purpose of improving the problem of solubility of the camptothecin, making the drug camptothecin have a targeted effect, reducing the toxic and side effects on normal cells and tissue, so as to achieve the specific anti-tumor purpose.

The invention discloses a camptothecin (CPT) predrug as well as a preparation method and application thereof. The CPT predrug takes vitamin B6 as a hydrophilic end and CPT as a hydrophobic end, and the two parts are connected through a disfulfide bond. The CPT predrug can realize self-assembly in water to form a pH/redox double-sensitive nano-drug delivery system, the nano-drug delivery system hascertain acid sensitivity and redox sensitivity, under the action of high-concentration glutathione in a tumor microenvironment, the disulfide bond can be broken quickly and release the CPT, the drugCPT can be delivered to a tumor part efficiently, and the safety and effectiveness of CPT drug delivery are expected to be further improved.

The invention relates to composite porous microspheres and a preparation method and application thereof. According to a composite porous microsphere preparation and a preparation method and application thereof, the composite porous microsphere preparation comprises the following components: chitosan and derivatives thereof, sulfonated chitosan oligosaccharide and sodium alginate. The prepared microspheres of the invention have the advantages of being easy to collect, adjustable in size and the like, and not only have a good swelling degree suitable for embolism, but also have high drug loading capacity; release of the drug loaded on the microspheres at a tumor part can be used for tumor treatment, so that the physical therapy effect on the tumor is further enhanced.

The invention relates to the field of biomedicine. More specifically, the present invention relates to an intestinal cancer peritoneal metastasis prediction model and a construction method thereof. The intestinal cancer peritoneal metastasis prediction model is as follows: Model=32.892 + 1.51 * CT_stage + 1.884*tumor location + 20.447*distant metastatic sites - 19.898*thickened greater omentum - 20.222*pelvic nodules, wherein the CT_stage is a T stage, the tumor location is a tumor site, the tumor location is a tumor site, the distant metastatic sites are used as far transfer parts, the thickened greater omentum is used for thickening the omentum majus, and the pelvic nodules are pelvic implant nodules. The intestinal cancer peritoneal metastasis prediction model is high in prediction accuracy and has high sensitivity and specificity.

The invention relates to a method for preparing a hyaluronic acid oligosaccharide encased paclitaxel liposome. The method comprises the following steps of: weighing phospholipids and paclitaxel to prepare a phospholipids-paclitaxel honeycomb-type thin film; hydrating the prepared thin film; preincubating oligosaccharide and ethyl dimethyl amine propyl carbodiimide in an acetate buffering solution; adding the hydrated suspension into an oligosaccharide-acetate buffering solution for incubation; and separating an obtained mixture to obtain the hyaluronic acid oligosaccharide encased paclitaxel liposome. The oligosaccharide encased paclitaxel liposome is uniform in size, high in encapsulation rate and stable in property; and the solubility of paclitaxel in water is effectively improved. Furthermore, for CD44 high-expression cancer cells (such as the breast cancer), the compound has relatively high targeting (hyaluronic acid is capable of specifically combining with CD44); the concentration of paclitaxel on a tumor part can be effectively increased; the using amount of paclitaxel is reduced; and the toxicity of a medicine on a human body is reduced, and the biological utilization rate is enhanced.

The present invention relates to a medicine for diagnosing carcinoma of stomach and its preparation method. Said medicine includes antibody and radioactive nuclide, the descried antibody is monoclonal antibody 3H11, and the described radioactive nuclide can utilize a bifunctional connecting agent to mark the described monoclonal antibody 3H11, and the monoclonal antibody marked by the described radioactive nuclide is a colourless transparent liquid injection. Because the tumor cell surface can express specific antigen, so that it can utilize the specific combination of antibody and antigen, and utilize said antibody to make the radioactive nuclide be loaded on the tumor region, and utilize nuclear medicine image technique to make diagnosis and location of tumor.